Literature DB >> 2117930

Suppression of established atherosclerosis and xanthomas in mature WHHL rabbits by keeping their serum cholesterol levels extremely low. Effect of pravastatin sodium in combination with cholestyramine.

M Shiomi1, T Ito, Y Watanabe, Y Tsujita, M Kuroda, M Arai, M Fukami, J Fukushige, A Tamura.   

Abstract

We investigated the possibility that established atherosclerosis and xanthomas in mature WHHL rabbits could be suppressed or even regressed when their serum cholesterol levels were kept extremely low. Ten-month-old WHHL rabbits were divided into 3 groups, i.e. control rabbits, sacrificed at age 10 months, and placebo and treated rabbits, sacrificed at age 18 months. The treated rabbits were given pravastatin sodium (50 mg/kg/day), an HMG-CoA reductase inhibitor, in combination with cholestyramine (2% in diet), a bile acid sequestrant, for 36 weeks. The serum cholesterol levels and atherogenic lipoproteins in the treated group were markedly reduced, by about 60% (P less than 0.005 and P less than 0.001). Consequently, the degrees of both coronary and aortic atherosclerosis in the treated group were significantly reduced compared with the placebo group, and were almost the same as in the control group. The histopathological findings supported the above results. In addition, the incidence and degree of xanthomas in digital joints in the treated group were significantly reduced. These results suggest that established atherosclerosis and xanthomas in mature WHHL rabbits could be suppressed by keeping their serum cholesterol levels extremely low by the combination drug treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2117930     DOI: 10.1016/0021-9150(90)90132-3

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  8 in total

1.  Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits.

Authors:  M Shiomi; T Ito
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

Review 2.  Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

Review 3.  Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease.

Authors:  M Haria; D McTavish
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

Review 4.  Pravastatin: a review of its use in elderly patients.

Authors:  Lynne M Bang; Karen L Goa
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

5.  Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/lipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions.

Authors:  M Shiomi; S Yamada; Y Amano; T Nishimoto; T Ito
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

6.  Cholesterol-fed ovariectomized monkeys are good animal models for human atherosclerosis of postmenopausal women.

Authors:  Ryuzo Torii; Masashi Shiomi; Takashi Ito; Satoshi Yamada; Yutaka Eguchi; Norimichi Ikeda
Journal:  Primates       Date:  2003-04-25       Impact factor: 2.163

Review 7.  Roles of the WHHL rabbit in translational research on hypercholesterolemia and cardiovascular diseases.

Authors:  Tsutomu Kobayashi; Takashi Ito; Masashi Shiomi
Journal:  J Biomed Biotechnol       Date:  2011-04-19

8.  The History of the WHHL Rabbit, an Animal Model of Familial Hypercholesterolemia (II) - Contribution to the Development and Validation of the Therapeutics for Hypercholesterolemia and Atherosclerosis.

Authors:  Masashi Shiomi
Journal:  J Atheroscler Thromb       Date:  2019-11-21       Impact factor: 4.928

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.